Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

Exclusion Criteria

• •Patients with severe substance disorder other than tobacco or caffeine use disorder; only severe substance use disorder is exclusionary for cannabis use
• •Liver, or renal dysfunction
• •A positive drug urine screen other than cannabis as per PI discretion
• •Sexually active females of child-bearing age not on a regular contraceptive, or nursing or with a positive pregnancy test
• •Clinical or laboratory evidence of uncompensated cardiovascular, endocrine, haematological, or pulmonary disease
• •History of reactive hypoglycaemia
• •Treatment within 3 months, or failure to tolerate GLP-1RA
• •Type 1 Diabetes (T1D) or current diagnosis of Type 2 Diabetes (T2D), diagnosis of T2D on OGTT screen, or HbA1c \> 6.5%
• •Use of Health Canada approved weight-lowering agents, warfarin, coumarin derivatives, or medication with significant renal impact
• •Major medical or surgical event within the preceding 3 months
• •Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome
• •History of pancreatitis or elevated amylase on screen
• •History of severe gastrointestinal disease, (i.e. gastroparesis)
• •Acute suicidal risk
• •Uncompensated thyroid disorder
• •History of heart rhythm disturbances, conduction system abnormalities, or evidence of clinically relevant abnormalities on screening ECG.
• •Any condition that interferes with the safe acquisition of MRI data such as metal implants, pacemakers, aneurysm clips, cochlear implants (only for the MRI component; can participate in the remainder of the trial)
• •History of gallstones with intact gallbladder or those at increased risk of gallbladder complications (with intact gallbladder)